P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2)

• A. Spira,
• L. Liao,
• X. Zhou,
• A. Gnanasakthy,
• L. Chen,
• D. Ungar,
• E. Yu,
• T. Kilavuz,
• J. Radford,
• M. Hamadani

Affiliations

A. Spira

1 Virginia Cancer Specialists Research Institute, Fairfax, VA

L. Liao

2 ADC Therapeutics America Inc., New Providence, NJ

X. Zhou

3 RTI Health Solutions, Research Triangle Park, NC, United States of America

A. Gnanasakthy

3 RTI Health Solutions, Research Triangle Park, NC, United States of America

L. Chen

2 ADC Therapeutics America Inc., New Providence, NJ

D. Ungar

2 ADC Therapeutics America Inc., New Providence, NJ

E. Yu

2 ADC Therapeutics America Inc., New Providence, NJ

T. Kilavuz

2 ADC Therapeutics America Inc., New Providence, NJ

J. Radford

4 NIHR Clinical Research Facility, the Christie NHS Foundation Trust and University of Manchester, Manchester Academic Health Centre, Manchester, United Kingdom

M. Hamadani

5 Medical College of Wisconsin, Division of Hematology & Oncology, Milwaukee, WI, United States of America